Konstan, Michael W.

A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation

Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 2,195

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 1,622

Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis

Konstan, M. W., Butler, S. M., Wohl, M. E. B., Stoddard, M., Matousek, R., Wagener, J. S., Johnson, C. A., & Morgan, W. J. (2003) · The Journal of Pediatrics

Cystic Fibrosis Research AdvancesClinical Nutrition and Gastroenterology

Cited by 393

Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries

Volkova, N., Moy, K., Evans, J., Campbell, D., Tian, S., Simard, C., Higgins, M., Konstan, M. W., Sawicki, G. S., Elbert, A., et al. (2020) · Journal of Cystic Fibrosis

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 258

Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data

Sawicki, G. S., McKone, E. F., Pasta, D. J., Millar, S. J., Wagener, J. S., Johnson, C. A., & Konstan, M. W. (2015) · American Journal of Respiratory and Critical Care Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 236

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor

Bessonova, L., Volkova, N., Higgins, M., Bengtsson, L., Tian, S., Simard, C., Konstan, M. W., Sawicki, G. S., Sewall, A., Nyangoma, S., et al. (2018) · Thorax

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 214

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)

McKone, E. F., Borowitz, D., Drevinek, P., Griese, M., Konstan, M. W., Wainwright, C., Ratjen, F., Sermet-Gaudelus, I., Plant, B., Munck, A., et al. (2014) · The Lancet Respiratory Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 211

Lung function decline from adolescence to young adulthood in cystic fibrosis

VandenBranden, S. L., McMullen, A., Schechter, M. S., Pasta, D. J., Michaelis, R. L., Konstan, M. W., Wagener, J. S., Morgan, W. J., McColley, S. A., & for the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis (2012) · Pediatric Pulmonology

Cystic Fibrosis Research AdvancesChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 128

Risk factors for rate of decline in FEV1 in adults with cystic fibrosis

Konstan, M. W., Wagener, J. S., VanDevanter, D. R., Pasta, D. J., Yegin, A., Rasouliyan, L., & Morgan, W. J. (2012) · Journal of Cystic Fibrosis

Cystic Fibrosis Research AdvancesChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 115

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR

Rowe, S. M., McColley, S. A., Rietschel, E., Li, X., Bell, S. C., Konstan, M. W., Marigowda, G., Waltz, D., & Boyle, M. P. (2017) · Annals of the American Thoracic Society

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 92